A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials

References

• Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the united states: A decision tree analysis. Cornea. 2011;30(4):379–87. doi:10.1097/ICO.0b013e3181f7f363.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–65. doi:10.1016/j.jtos.2017.05.003.
   PubMed Web of Science ®Google Scholar
• Khan RS, Rizvi S, Syed BA, Bielory L. Current market trends in anterior ocular inflammatory disease landscape. Curr Opin Allergy Clin Immunol. 2019;19(5):503–09. doi:10.1097/ACI.0000000000000562.
   PubMed Web of Science ®Google Scholar
• Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, Rocha EM. Dry eye disease treatment: A systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11(3):181–92. doi:10.1016/j.jtos.2013.02.002.
   PubMed Web of Science ®Google Scholar
• CEQUATM (cyclosporine opthalmic solution 0.09%). Full prescribing information. Cranbury (NJ): Sun Pharmaceutical Industries, Inc.; 2018.
   Google Scholar
• Ikervis® (ciclosporin ophthalmic emulsion) 1 mg/ml, for topical ophthalmic use. Full prescribing information. Evry (France): SantenSAS; 2015.
   Google Scholar
• RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for topical ophthalmic use. Full prescribing information. Irvine (CA): Allergan; 2017.
   Google Scholar
• XiidraTM (lifitegrast ophthalmic solution) 5%, for topical ophthalmic use. Lexington (MA): Shire US, Inc.; 2016.
   Google Scholar
• Novack GD, Asbell P, Barabino S, Bergamini MVW, Ciolino JB, Foulks GN, Goldstein M, Lemp MA, Schrader S, Woods C, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017;15(3):629–49. doi:10.1016/j.jtos.2017.05.009.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Csa phase 3 study group. Ophthalmology. 2000;107(4):631–39. doi:10.1016/S0161-6420(99)00176-1.
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Ousler GW. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (Sar 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153:1050–1060 e1051.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: A multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–96. doi:10.5301/ejo.5000779.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, D’Ambrosio FA Jr., McLaurin EB, Eiferman RA, Kennedy KS, Semba CP; Group Opus- Study. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the Opus-1 phase 3 study. Ophthalmology. 2014;121(2):475–83. doi:10.1016/j.ophtha.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; Investigators Opus-. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III Opus-2 study. Ophthalmology. 2015;122(12):2423–31. doi:10.1016/j.ophtha.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (Opus-3). Ophthalmology. 2017;124(1):53–60. doi:10.1016/j.ophtha.2016.09.025.
   PubMed Web of Science ®Google Scholar
• Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921–29. doi:10.2147/OPTH.S175065.
   PubMed Web of Science ®Google Scholar
• Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126(9):1230–37. doi:10.1016/j.ophtha.2019.03.050.
   PubMed Web of Science ®Google Scholar
• Dekker M. Statistical methodology in the pharmaceutical sciences. New York.
   Google Scholar
• Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531–41. doi:10.1111/jphp.12075.
   PubMed Web of Science ®Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target. 2004;12(9–10):623–33. doi:10.1080/10611860400015910.
   PubMed Web of Science ®Google Scholar
• Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(5):422–37. doi:10.1002/wnan.1272.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 2010;5(3):485–505. doi:10.2217/nnm.10.10.
   PubMed Web of Science ®Google Scholar
• Tanford C. Thermodynamics of micelle formation: prediction of micelle size and size distribution. Proc Natl Acad Sci U S A. 1974;71(5):1811–15. doi:10.1073/pnas.71.5.1811.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol. 2015;4(3):1. doi:10.1167/tvst.4.3.1.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed. 2012;2(2):82–95. doi:10.2174/1877912311202020082.
   PubMedGoogle Scholar
• Vadlapudi AD, Mitra AK. Nanomicelles: an emerging platform for drug delivery to the eye. Ther Deliv. 2013;4(1):1–3. doi:10.4155/tde.12.122.
   PubMedGoogle Scholar
• Benitez-Del-Castillo JM, Moreno-Montanes J, Jimenez-Alfaro I, Munoz-Negrete FJ, Turman K, Palumaa K, Sadaba B, Gonzalez MV, Ruz V, Vargas B, et al. Safety and efficacy clinical trials for Syl1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447–54. doi:10.1167/iovs.16-20303.
   PubMed Web of Science ®Google Scholar
• Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jentsch G, Beckert M, Ousler G, Steven P, Krosser S. A clinical phase 2 study to assess efficacy, safety and tolerability of cyclasol(®) for treatment of dry eye disease (ded). Ophthalmology. 2019;126:792–800. doi:10.1016/j.ophtha.2019.01.024.
   PubMed Web of Science ®Google Scholar
• Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: A randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (cae) model. Clin Ophthalmol. 2015;9:877–84.
   PubMed Web of Science ®Google Scholar